196170ALTEOGEN196170 info
$240.85info1.11%24h
Global rank3768
Market cap$3.27B
Change 7d2.24%
YTD Performance229.72%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Business data

    ALTEOGEN (196170) Stock Overview

    ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

    196170 Stock Information

    Symbol
    196170
    Address
    62, Yuseong-daeroDaejeon, 34054South Korea
    Founded
    -
    Trading hours
    -
    Website
    https://www.alteogen.com
    Country
    🇰🇷 South Korea
    Phone Number
    82 4 2384 8780

    ALTEOGEN (196170) Price Chart

    -
    Value:-

    ALTEOGEN Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $240.85
    N/A
    Market Cap
    $3.27B
    N/A
    Shares Outstanding
    13.58M
    N/A
    Employees
    128.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org